|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vousden KH and Lane DP: p53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar
|
|
3
|
Gleber-Netto FO, Zhao M, Trivedi S, Wang
J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN Jr,
et al: Distinct pattern of TP53 mutations in human immunodeficiency
virus-related head and neck squamous cell carcinoma. Cancer.
124:84–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berkers CR, Maddocks OD, Cheung EC, Mor I
and Vousden KH: Metabolic regulation by p53 family members. Cell
Metab. 18:617–633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goldstein I and Rotter V: Regulation of
lipid metabolism by p53-fighting two villains with one sword.
Trends Endocrinol Metab. 23:567–575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnson DE, Burtness B, Leemans CR, Lui
VWY, Bauman JE and Grandis JR: Head and neck squamous cell
carcinoma. Nat Rev Dis Primers. 6:922020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Saraniti C, Speciale R, Santangelo M,
Massaro N, Maniaci A, Gallina S, Serra A and Cocuzza S: Functional
outcomes after supracricoid modified partial laryngectomy. J Biol
Regul Homeost Agents. 33:1903–1907. 2019.PubMed/NCBI
|
|
9
|
Nissi L, Suilamo S, Kytö E, Vaittinen S,
Irjala H and Minn H: Recurrence of head and neck squamous cell
carcinoma in relation to high-risk treatment volume. Clin Transl
Radiat Oncol. 27:139–146. 2021.
|
|
10
|
Ma L, Men Y, Feng L, Kang J, Sun X, Yuan
M, Jiang W and Hui Z: A current review of dose-escalated
radiotherapy in locally advanced non-small cell lung cancer. Radiol
Oncol. 53:6–14. 2019. View Article : Google Scholar
|
|
11
|
Chen X, Comish PB, Tang D and Kang R:
Characteristics and biomarkers of ferroptosis. Front Cell Dev Biol.
9:6371622021. View Article : Google Scholar
|
|
12
|
Gorrini C, Harris IS and Mak TW:
Modulation of oxidative stress as an anticancer strategy. Nat Rev
Drug Discov. 12:931–947. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma S, Henson ES, Chen Y and Gibson SB:
Ferroptosis is induced following siramesine and lapatinib treatment
of breast cancer cells. Cell Death Dis. 7:e23072016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun X, Niu X, Chen R, He W, Chen D, Kang R
and Tang D: Metallothionein-1G facilitates sorafenib resistance
through inhibition of ferroptosis. Hepatology. 64:488–500. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C,
Dai X, Li Z and Wu G: Ferroptosis: A novel anti-tumor action for
cisplatin. Cancer Res Treat. 50:445–460. 2018. View Article : Google Scholar
|
|
16
|
Shi Y, Wei W, Li L, Wei Q, Jiang F, Xia G
and Yu H: The global status of research in breast cancer liver
metastasis: A bibliometric and visualized analysis. Bioengineered.
12:12246–12262. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schaue D and McBride WH: Opportunities and
challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol.
12:527–540. 2015. View Article : Google Scholar
|
|
18
|
Sierko E, Hempel D, Zuzda K and
Wojtukiewicz MZ: Personalized radiation therapy in cancer pain
management. Cancers (Basel). 11:3902019. View Article : Google Scholar
|
|
19
|
Stevens S, Moloney S, Blackmore A, Hart C,
Rixham P, Bangiri A, Pooler A and Doolan P: IPEM topical report:
Guidance for the clinical implementation of online treatment
monitoring solutions for IMRT/VMAT. Phys Med Biol.
68:10.1088/1361–6560/acecd0. 2023. View Article : Google Scholar
|
|
20
|
Gao S, Xu Q, Lan Y and He L: Recurrent
trichilemmal carcinoma of the periorbital region treated with IMRT
radiotherapy: A case report and a review of literature. Medicine
(Baltimore). 102:e340382023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Machiels JP, René Leemans C, Golusinski W,
Grau C, Licitra L and Gregoire V; EHNS Executive Board: ESMO
Guidelines Committee, : ESTRO Executive Board: Reprint of ‘Squamous
cell carcinoma of the oral cavity, larynx, oropharynx and
hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for
diagnosis, treatment and follow-up’. Oral Oncol. 113:1050422021.
View Article : Google Scholar
|
|
22
|
Galluzzi L, Vitale I, Aaronson SA, Abrams
JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews
DW, et al: Molecular mechanisms of cell death: Recommendations of
the Nomenclature Committee on Cell Death 2018. Cell Death Differ.
25:486–541. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang D, Kang R, Berghe TV, Vandenabeele P
and Kroemer G: The molecular machinery of regulated cell death.
Cell Res. 29:347–364. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kroemer G, Galluzzi L, Vandenabeele P,
Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS,
Golstein P, Green DR, et al: Classification of cell death:
Recommendations of the Nomenclature committee on cell death 2009.
Cell Death Differ. 16:3–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Povirk LF: Biochemical mechanisms of
chromosomal translocations resulting from DNA double-strand breaks.
DNA Repair (Amst). 5:1199–1212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mladenov E, Magin S, Soni A and Iliakis G:
DNA double-strand break repair as determinant of cellular
radiosensitivity to killing and target in radiation therapy. Front
Oncol. 3:1132013. View Article : Google Scholar
|
|
27
|
Vermorken JB, Remenar E, van Herpen C,
Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss
JH, et al: Cisplatin, fluorouracil, and docetaxel in unresectable
head and neck cancer. N Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Brizel DM and Esclamado R: Concurrent
chemoradiotherapy for locally advanced, nonmetastatic, squamous
carcinoma of the head and neck: Consensus, controversy, and
conundrum. J Clin Oncol. 24:2612–2617. 2006. View Article : Google Scholar
|
|
29
|
Ghosh C, Luong G and Sun Y: A snapshot of
the PD-1/PD-L1 pathway. J Cancer. 12:2735–2746. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ferris RL and Licitra L: PD-1
immunotherapy for recurrent or metastatic HNSCC. Lancet.
394:1882–1884. 2019. View Article : Google Scholar
|
|
31
|
Seiwert TY, Burtness B, Mehra R, Weiss J,
Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et
al: Safety and clinical activity of pembrolizumab for treatment of
recurrent or metastatic squamous cell carcinoma of the head and
neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial.
Lancet Oncol. 17:956–965. 2016. View Article : Google Scholar
|
|
32
|
Cohen EEW, Soulières D, Le Tourneau C,
Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R,
et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab
for recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet.
393:156–167. 2019. View Article : Google Scholar
|
|
33
|
Burtness B, Harrington KJ, Greil R,
Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane
P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KEYNOTE-048): A
randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019.
View Article : Google Scholar
|
|
34
|
Haddad RI, Harrington K, Tahara M, Ferris
RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B,
Taberna M, et al: Nivolumab plus ipilimumab versus EXTREME Regimen
as First-Line treatment for Recurrent/Metastatic squamous cell
carcinoma of the head and neck: The final results of CheckMate 651.
J Clin Oncol. 41:2166–2180. 2023. View Article : Google Scholar
|
|
35
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE,
Even C, et al: Nivolumab vs investigator's choice in recurrent or
metastatic squamous cell carcinoma of the head and neck: 2-year
long-term survival update of CheckMate 141 with analyses by tumor
PD-L1 expression. Oral Oncol. 81:45–51. 2018. View Article : Google Scholar
|
|
37
|
Wise-Draper TM, Gulati S, Palackdharry S,
Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y,
Riaz MK, et al: Phase II clinical trial of neoadjuvant and adjuvant
pembrolizumab in resectable local-regionally advanced head and neck
squamous cell carcinoma. Clin Cancer Res. 28:1345–1352. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Druker BJ: David A. Karnofsky Award
lecture. Imatinib as a paradigm of targeted therapies. J Clin
Oncol. 21 (23 Suppl):239S–245S. 2003. View Article : Google Scholar
|
|
39
|
Xu MJ, Johnson DE and Grandis JR:
EGFR-targeted therapies in the post-genomic era. Cancer Metastasis
Rev. 36:463–473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Parmar K, Mohamed A, Vaish E, Thawani R,
Cetnar J and Thein KZ: Immunotherapy in head and neck squamous cell
carcinoma: An updated review. Cancer Treat Res Commun.
33:1006492022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dougan M and Dranoff G: Immune therapy for
cancer. Annu Rev Immunol. 27:83–117. 2009. View Article : Google Scholar
|
|
42
|
Correale P, Botta C, Cusi MG, Del Vecchio
MT, De Santi MM, Gori Savellini G, Bestoso E, Apollinari S,
Mannucci S, Marra M, et al: Cetuximab ± chemotherapy enhances
dendritic cell-mediated phagocytosis of colon cancer cells and
ignites a highly efficient colon cancer antigen-specific cytotoxic
T-cell response in vitro. Int J Cancer. 130:1577–1589. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Maréchal R, De Schutter J, Nagy N,
Demetter P, Lemmers A, Devière J, Salmon I, Tejpar S and Van
Laethem JL: Putative contribution of CD56 positive cells in
cetuximab treatment efficacy in first-line metastatic colorectal
cancer patients. BMC Cancer. 10:3402010. View Article : Google Scholar
|
|
44
|
Dechant M, Weisner W, Berger S, Peipp M,
Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK,
Parren PW, van de Winkel JG and Valerius T: Complement-dependent
tumor cell lysis triggered by combinations of epidermal growth
factor receptor antibodies. Cancer Res. 68:4998–5003. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hsu YF, Ajona D, Corrales L, Lopez-Picazo
JM, Gurpide A, Montuenga LM and Pio R: Complement activation
mediates cetuximab inhibition of non-small cell lung cancer tumor
growth in vivo. Mol Cancer. 9:1392010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar
|
|
47
|
Wang Y, Wang Y, Pan J, Gan L and Xue J:
Ferroptosis, necroptosis, and pyroptosis in cancer: Crucial cell
death types in radiotherapy and post-radiotherapy immune
activation. Radiother Oncol. 184:1096892023. View Article : Google Scholar
|
|
48
|
Stockwell BR, Jiang X and Gu W: Emerging
mechanisms and disease relevance of ferroptosis. Trends Cell Biol.
30:478–490. 2020. View Article : Google Scholar
|
|
49
|
Liang W and Ferrara N: Iron metabolism in
the tumor microenvironment: Contributions of innate immune cells.
Front Immunol. 11:6268122021. View Article : Google Scholar
|
|
50
|
Galaris D, Barbouti A and Pantopoulos K:
Iron homeostasis and oxidative stress: An intimate relationship.
Biochim Biophys Acta Mol Cell Res. 1866:1185352019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
He YJ, Liu XY, Xing L, Wan X, Chang X and
Jiang HL: Fenton reaction-independent ferroptosis therapy via
glutathione and iron redox couple sequentially triggered lipid
peroxide generator. Biomaterials. 241:1199112020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zheng J and Conrad M: The metabolic
underpinnings of ferroptosis. Cell Metab. 32:920–937. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Roh JL, Kim EH, Jang HJ, Park JY and Shin
D: Induction of ferroptotic cell death for overcoming cisplatin
resistance of head and neck cancer. Cancer Lett. 381:96–103. 2016.
View Article : Google Scholar
|
|
54
|
Roh JL, Kim EH, Jang H and Shin D: Nrf2
inhibition reverses the resistance of cisplatin-resistant head and
neck cancer cells to artesunate-induced ferroptosis. Redox Biol.
11:254–262. 2017. View Article : Google Scholar
|
|
55
|
Kim EH, Shin D, Lee J, Jung AR and Roh JL:
CISD2 inhibition overcomes resistance to sulfasalazine-induced
ferroptotic cell death in head and neck cancer. Cancer Lett.
432:180–190. 2018. View Article : Google Scholar
|
|
56
|
Lin R, Zhang Z, Chen L, Zhou Y, Zou P,
Feng C, Wang L and Liang G: Dihydroartemisinin (DHA) induces
ferroptosis and causes cell cycle arrest in head and neck carcinoma
cells. Cancer Lett. 381:165–175. 2016. View Article : Google Scholar
|
|
57
|
Tang D, Chen X, Kang R and Kroemer G:
Ferroptosis: Molecular mechanisms and health implications. Cell
Res. 31:107–125. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lei G, Zhuang L and Gan B: Targeting
ferroptosis as a vulnerability in cancer. Nat Rev Cancer.
22:381–396. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Friedmann Angeli JP, Schneider M, Proneth
B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch
A, Eggenhofer E, et al: Inactivation of the ferroptosis regulator
Gpx4 triggers acute renal failure in mice. Nat Cell Biol.
16:1180–1191. 2014. View Article : Google Scholar
|
|
60
|
Dixon SJ, Patel DN, Welsch M, Skouta R,
Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS
and Stockwell BR: Pharmacological inhibition of cystine-glutamate
exchange induces endoplasmic reticulum stress and ferroptosis.
Elife. 3:e025232014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sato H, Tamba M, Ishii T and Bannai S:
Cloning and expression of a plasma membrane cystine/glutamate
exchange transporter composed of two distinct proteins. J Biol
Chem. 274:11455–11458. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Koppula P, Zhuang L and Gan B: Cystine
transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient
dependency, and cancer therapy. Protein Cell. 12:599–620. 2021.
View Article : Google Scholar
|
|
63
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar
|
|
64
|
Shi JF, Liu Y, Wang Y, Gao R, Wang Y and
Liu J: Targeting ferroptosis, a novel programmed cell death, for
the potential of alcohol-related liver disease therapy. Front
Pharmacol. 14:11943432023. View Article : Google Scholar
|
|
65
|
Seibt TM, Proneth B and Conrad M: Role of
GPX4 in ferroptosis and its pharmacological implication. Free Radic
Biol Med. 133:144–152. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Maiorino M, Conrad M and Ursini F: GPx4,
Lipid peroxidation, and cell death: Discoveries, rediscoveries, and
open issues. Antioxid Redox Signal. 29:61–74. 2018. View Article : Google Scholar
|
|
67
|
Bersuker K, Hendricks JM, Li Z, Magtanong
L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al:
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit
ferroptosis. Nature. 575:688–692. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wu M, Xu LG, Li X, Zhai Z and Shu HB:
AMID, an apoptosis-inducing factor-homologous
mitochondrion-associated protein, induces caspase-independent
apoptosis. J Biol Chem. 277:25617–25623. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Marshall KR, Gong M, Wodke L, Lamb JH,
Jones DJ, Farmer PB, Scrutton NS and Munro AW: The human
apoptosis-inducing protein AMID is an oxidoreductase with a
modified flavin cofactor and DNA binding activity. J Biol Chem.
280:30735–30740. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Elguindy MM and Nakamaru-Ogiso E:
Apoptosis-inducing factor (AIF) and its family member protein,
AMID, are rotenone-sensitive NADH:Ubiquinone oxidoreductases
(NDH-2). J Biol Chem. 290:20815–20826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Doll S, Freitas FP, Shah R, Aldrovandi M,
da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius
E, Scheel CH, et al: FSP1 is a glutathione-independent ferroptosis
suppressor. Nature. 575:693–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Shimada K, Skouta R, Kaplan A, Yang WS,
Hayano M, Dixon SJ, Brown LM, Valenzuela CA, Wolpaw AJ and
Stockwell BR: Global survey of cell death mechanisms reveals
metabolic regulation of ferroptosis. Nat Chem Biol. 12:497–503.
2016. View Article : Google Scholar
|
|
73
|
Xu J, Wu Y, Song P, Zhang M, Wang S and
Zou MH: Proteasome-dependent degradation of guanosine
5′-triphosphate cyclohydrolase I causes tetrahydrobiopterin
deficiency in diabetes mellitus. Circulation. 116:944–953. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Soula M, Weber RA, Zilka O, Alwaseem H, La
K, Yen F, Molina H, Garcia-Bermudez J, Pratt DA and Birsoy K:
Metabolic determinants of cancer cell sensitivity to canonical
ferroptosis inducers. Nat Chem Biol. 16:1351–1360. 2020. View Article : Google Scholar
|
|
75
|
Kraft VAN, Bezjian CT, Pfeiffer S,
Ringelstetter L, Müller C, Zandkarimi F, Merl-Pham J, Bao X,
Anastasov N, Kössl J, et al: GTP Cyclohydrolase
1/Tetrahydrobiopterin counteract ferroptosis through lipid
remodeling. ACS Cent Sci. 6:41–53. 2020. View Article : Google Scholar
|
|
76
|
Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee
H, Koppula P, Wu S, Zhuang L, Fang B, et al: DHODH-mediated
ferroptosis defence is a targetable vulnerability in cancer.
Nature. 593:586–590. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ward JF: DNA damage produced by ionizing
radiation in mammalian cells: Identities, mechanisms of formation,
and reparability. Prog Nucleic Acid Res Mol Biol. 35:95–125. 1988.
View Article : Google Scholar
|
|
78
|
Santivasi WL and Xia F: Ionizing
radiation-induced DNA damage, response, and repair. Antioxid Redox
Signal. 21:251–259. 2014. View Article : Google Scholar
|
|
79
|
Azzam EI, Jay-Gerin JP and Pain D:
Ionizing radiation-induced metabolic oxidative stress and prolonged
cell injury. Cancer Lett. 327:48–60. 2012. View Article : Google Scholar
|
|
80
|
Reisz JA, Bansal N, Qian J, Zhao W and
Furdui CM: Effects of ionizing radiation on biological
molecules-mechanisms of damage and emerging methods of detection.
Antioxid Redox Signal. 21:260–292. 2014. View Article : Google Scholar
|
|
81
|
Adjemian S, Oltean T, Martens S, Wiernicki
B, Goossens V, Van den Berghe T, Cappe B, Ladik M, Riquet FB,
Heyndrickx L, et al: Ionizing radiation results in a mixture of
cellular outcomes including mitotic catastrophe, senescence,
methuosis, and iron-dependent cell death. Cell Death Dis.
11:10032020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Srinivas US, Tan BWQ, Vellayappan BA and
Jeyasekharan AD: ROS and the DNA damage response in cancer. Redox
Biol. 25:1010842019. View Article : Google Scholar
|
|
83
|
Yang WS, Kim KJ, Gaschler MM, Patel M,
Shchepinov MS and Stockwell BR: Peroidation of polyunsaturated
fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci
USA. 113:E4966–E4975. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Lei G, Mao C, Yan Y, Zhuang L and Gan B:
Ferroptosis, radiotherapy, and combination therapeutic strategies.
Protein Cell. 12:836–857. 2021. View Article : Google Scholar
|
|
85
|
Herrera FG, Irving M, Kandalaft LE and
Coukos G: Rational combinations of immunotherapy with radiotherapy
in ovarian cancer. Lancet Oncol. 20:e417–e433. 2019. View Article : Google Scholar
|
|
86
|
Lang X, Green MD, Wang W, Yu J, Choi JE,
Jiang L, Liao P, Zhou J, Zhang Q, Dow A, et al: Radiotherapy and
immunotherapy promote tumoral lipid oxidation and ferroptosis via
synergistic repression of SLC7A11. Cancer Discov. 9:1673–1685.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Doll S, Proneth B, Tyurina YY, Panzilius
E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A,
et al: ACSL4 dictates ferroptosis sensitivity by shaping cellular
lipid composition. Nat Chem Biol. 13:91–98. 2017. View Article : Google Scholar
|
|
88
|
Wang H, An P, Xie E, Wu Q, Fang X, Gao H,
Zhang Z, Li Y, Wang X, Zhang J, et al: Characterization of
ferroptosis in murine models of hemochromatosis. Hepatology.
66:449–465. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Dong H, Qiang Z, Chai D, Peng J, Xia Y, Hu
R and Jiang H: Nrf2 inhibits ferroptosis and protects against acute
lung injury due to intestinal ischemia reperfusion via regulating
SLC7A11 and HO-1. Aging (Albany NY). 12:12943–12959. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wei R, Zhao Y, Wang J, Yang X, Li S, Wang
Y, Yang X, Fei J, Hao X, Zhao Y, et al: Tagitinin C induces
ferroptosis through PERK-Nrf2-HO-1 signaling pathway in colorectal
cancer cells. Int J Biol Sci. 17:2703–2717. 2021. View Article : Google Scholar
|
|
91
|
Bump EA and Brown JM: Role of glutathione
in the radiation response of mammalian cells in vitro and in vivo.
Pharmacol Ther. 47:117–136. 1990. View Article : Google Scholar
|
|
92
|
Zou Y and Schreiber SL: Progress in
understanding ferroptosis and challenges in its targeting for
therapeutic benefit. Cell Chem Biol. 27:463–471. 2020. View Article : Google Scholar
|
|
93
|
Feng L, Zhao K, Sun L, Yin X, Zhang J, Liu
C and Li B: SLC7A11 regulated by NRF2 modulates esophageal squamous
cell carcinoma radiosensitivity by inhibiting ferroptosis. J Transl
Med. 19:3672021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Steinbichler TB, Dudás J, Skvortsov S,
Ganswindt U, Riechelmann H and Skvortsova II: Therapy resistance
mediated by exosomes. Mol Cancer. 18:582019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhang W, Sun Y, Bai L, Zhi L, Yang Y, Zhao
Q, Chen C, Qi Y, Gao W, He W, et al: RBMS1 regulates lung cancer
ferroptosis through translational control of SLC7A11. J Clin
Invest. 131:e1520672021. View Article : Google Scholar
|
|
96
|
Yang M, Wu X, Hu J, Wang Y, Wang Y, Zhang
L, Huang W, Wang X, Li N, Liao L, et al: COMMD10 inhibits HIF1α/CP
loop to enhance ferroptosis and radiosensitivity by disrupting
Cu-Fe balance in hepatocellular carcinoma. J Hepatol. 76:1138–1150.
2022. View Article : Google Scholar
|
|
97
|
Zheng Z, Su J, Bao X, Wang H, Bian C, Zhao
Q and Jiang X: Mechanisms and applications of radiation-induced
oxidative stress in regulating cancer immunotherapy. Front Immunol.
14:12472682023. View Article : Google Scholar
|
|
98
|
Koppula P, Lei G, Zhang Y, Yan Y, Mao C,
Kondiparthi L, Shi J, Liu X, Horbath A, Das M, et al: A targetable
CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1
inactive lung cancers. Nat Commun. 13:22062022. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Olcina MM, Grand RJ and Hammond EM: ATM
activation in hypoxia-causes and consequences. Mol Cell Oncol.
1:e299032014. View Article : Google Scholar
|
|
100
|
Fallone F, Britton S, Nieto L, Salles B
and Muller C: ATR controls cellular adaptation to hypoxia through
positive regulation of hypoxia-inducible factor 1 (HIF-1)
expression. Oncogene. 32:4387–4396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Olcina M, Lecane PS and Hammond EM:
Targeting hypoxic cells through the DNA damage response. Clin
Cancer Res. 16:5624–5629. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hammond EM, Asselin MC, Forster D,
O'Connor JP, Senra JM and Williams KJ: The meaning, measurement and
modification of hypoxia in the laboratory and the clinic. Clin
Oncol (R Coll Radiol). 26:277–288. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Xie L, Song X, Yu J, Guo W, Wei L, Liu Y
and Wang X: Solute carrier protein family may involve in
radiation-induced radioresistance of non-small cell lung cancer. J
Cancer Res Clin Oncol. 137:1739–1747. 2011. View Article : Google Scholar
|
|
104
|
Pan X, Lin Z, Jiang D, Yu Y, Yang D, Zhou
H, Zhan D, Liu S, Peng G, Chen Z and Yu Z: Erastin decreases
radioresistance of NSCLC cells partially by inducing GPX4-mediated
ferroptosis. Oncol Lett. 17:3001–3008. 2019.
|
|
105
|
Chen Q, Zheng W, Guan J, Liu H, Dan Y, Zhu
L, Song Y, Zhou Y, Zhao X, Zhang Y, et al: SOCS2-enhanced
ubiquitination of SLC7A11 promotes ferroptosis and
radiosensitization in hepatocellular carcinoma. Cell Death Differ.
30:137–151. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ivanov SD, Semenov AL, Kovan'ko EG and
Yamshanov VA: Effects of iron ions and iron chelation on the
efficiency of experimental radiotherapy of animals with gliomas.
Bull Exp Biol Med. 158:800–803. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Zhang Z, Lu M, Chen C, Tong X, Li Y, Yang
K, Lv H, Xu J and Qin L: Holo-lactoferrin: The link between
ferroptosis and radiotherapy in triple-negative breast cancer.
Theranostics. 11:3167–3182. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Shibata Y, Yasui H, Higashikawa K,
Miyamoto N and Kuge Y: Erastin, a ferroptosis-inducing agent,
sensitized cancer cells to X-ray irradiation via glutathione
starvation in vitro and in vivo. PLoS One. 14:e02259312019.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Ye LF, Chaudhary KR, Zandkarimi F, Harken
AD, Kinslow CJ, Upadhyayula PS, Dovas A, Higgins DM, Tan H, Zhang
Y, et al: Radiation-induced lipid peroxidation triggers ferroptosis
and synergizes with ferroptosis inducers. ACS Chem Biol.
15L:469–484. 2020. View Article : Google Scholar
|
|
110
|
Lei G, Zhang Y, Koppula P, Liu X, Zhang J,
Lin SH, Ajani JA, Xiao Q, Liao Z, Wang H and Gan B: The role of
ferroptosis in ionizing radiation-induced cell death and tumor
suppression. Cell Res. 30:146–162. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Jhunjhunwala S, Hammer C and Delamarre L:
Antigen presentation in cancer: Insights into tumour immunogenicity
and immune evasion. Nat Rev Cancer. 21:298–312. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Wang W, Green M, Choi JE, Gijón M, Kennedy
PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al: CD8+T
cells regulate tumour ferroptosis during cancer immunotherapy.
Nature. 569:270–274. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Xu L and Fan W: Efficacy of sorafenib
combined with radiofrequency ablation in renal cancer and its
effects on immunity and inflammation in patients. J BUON.
25:514–519. 2020.PubMed/NCBI
|
|
114
|
Li S, Liu Y, Li J, Zhao X and Yu D:
Mechanisms of Ferroptosis and application to head and neck squamous
cell carcinoma treatments. DNA Cell Biol. 40:720–732. 2021.
View Article : Google Scholar
|
|
115
|
Ma P, Xiao H, Yu C, Liu J, Cheng Z, Song
H, Zhang X, Li C, Wang J, Gu Z and Lin J: Enhanced cisplatin
chemotherapy by iron oxide nanocarrier-mediated generation of
highly toxic reactive oxygen species. Nano Lett. 17:928–937. 2017.
View Article : Google Scholar
|
|
116
|
Jiang X, Stockwell BR and Conrad M:
Ferroptosis: Mechanisms, biology and role in disease. Nat Rev Mol
Cell Biol. 22:266–282. 2021. View Article : Google Scholar
|
|
117
|
Gout PW, Buckley AR, Simms CR and
Bruchovsky N: Sulfasalazine, a potent suppressor of lymphoma growth
by inhibition of the x(c)-cystine transporter: A new action for an
old drug. Leukemia. 15:1633–1640. 2001. View Article : Google Scholar
|
|
118
|
Liang F, Wang R, Du Q and Zhu S: An
Epithelial-mesenchymal transition hallmark gene-based risk score
system in head and neck squamous-cell carcinoma. Int J Gen Med.
14:4219–4227. 2021. View Article : Google Scholar : PubMed/NCBI
|
